Program
aumolertinib
Also written as “Almonertinib”, “Aumolertinib” and “HS-10296”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by 4 companies.
Drug pageAumolertinib: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hansoh Pharmaceutical Groupits history only | 85 open or running | phase 3since Nov 23, 2018 | Nov 28, 2016 | none ahead |
| Jiangsu HengRui Medicineits history only | 43 open or running | phase 3since Sep 12, 2025 | Apr 2, 2019 | Jul 30, 2027phase 2 · NCT05503888 |
| EQRx International | 20 open or running | phase 3since Jun 24, 2022 | Nov 5, 2021 | none ahead |
| Revolution Medicinesits history only | 10 open or running | phase 1since Jul 13, 2021 | Jul 13, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of EQRx International only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 19, 2020Named aumolertinibINNProposed as its International Nonproprietary Name in WHO's List 124 · before, HS-10296
- Nov 5, 2021First study: phase 1 study in Severe Hepatic ImpairmentFirst studyNCT05199610 · 12 enrolled · United States
- Jun 24, 2022Phase 3 study in NSCLCNCT05493501 · 8 enrolled · United States
TargetBeta
“An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, ”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| zipalertinibrule | Otsuka | phase 3 | 4 |
Studies
All 2 EQRx International leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05493501NSCLC · United States | 3 | Terminated | Aug 31, 2023 | 8 |
| NCT05199610Severe Hepatic Impairment · United States | 1 | Completed | Apr 1, 2023 | 12 |
How it is read
Names in the registry
- “Almonertinib”, 3 entries
- “Aumolertinib”, 2 entries
- “aumolertinib”, 2 entries
- “HS-10296”, 2 entries
- “almonertinib”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 11 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.